Landscape of the intratumroal microenvironment in bladder cancer : Implications for prognosis and immunotherapy
© 2022 The Author(s)..
Introduction: This study aims to present the landscape of the intratumoral microenvironment and by which establish a classification system that can be used to predict the prognosis of bladder cancer patients and their response to anti-PD-L1 immunotherapy.
Methods: The expression profiles of 1554 bladder cancer cases were downloaded from seven public datasets. Single-sample gene set enrichment analysis (ssGSEA), univariate Cox regression analysis, and meta-analysis were employed to establish the bladder cancer immune prognostic index (BCIPI). Extensive analyses were executed to investigate the association between BCIPI and overall survival, tumor-infiltrated immunocytes, immunotherapeutic response, mutation load, etc.
Results: The results obtained from seven independent cohorts and meta-analyses suggested that the BCIPI is an effective classification system for estimating bladder cancer patients' overall survival. Patients in the BCIPI-High subgroup revealed different immunophenotypic outcomes from those in the BCIPI-Low subgroup regarding tumor-infiltrated immunocytes and mutated genes. Subsequent analysis suggested that patients in the BCIPI-High subgroup were more sensitive to anti-PD-L1 immunotherapy than those in the BCIPI-Low subgroup.
Conclusions: The newly established BCIPI is a valuable tool for predicting overall survival outcomes and immunotherapeutic responses in patients with bladder cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Computational and structural biotechnology journal - 21(2023) vom: 01., Seite 74-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bian, Zichen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 21.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.csbj.2022.11.052 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350263418 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350263418 | ||
| 003 | DE-627 | ||
| 005 | 20231226044619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.csbj.2022.11.052 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350263418 | ||
| 035 | |a (NLM)36514337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bian, Zichen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Landscape of the intratumroal microenvironment in bladder cancer |b Implications for prognosis and immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a Introduction: This study aims to present the landscape of the intratumoral microenvironment and by which establish a classification system that can be used to predict the prognosis of bladder cancer patients and their response to anti-PD-L1 immunotherapy | ||
| 520 | |a Methods: The expression profiles of 1554 bladder cancer cases were downloaded from seven public datasets. Single-sample gene set enrichment analysis (ssGSEA), univariate Cox regression analysis, and meta-analysis were employed to establish the bladder cancer immune prognostic index (BCIPI). Extensive analyses were executed to investigate the association between BCIPI and overall survival, tumor-infiltrated immunocytes, immunotherapeutic response, mutation load, etc | ||
| 520 | |a Results: The results obtained from seven independent cohorts and meta-analyses suggested that the BCIPI is an effective classification system for estimating bladder cancer patients' overall survival. Patients in the BCIPI-High subgroup revealed different immunophenotypic outcomes from those in the BCIPI-Low subgroup regarding tumor-infiltrated immunocytes and mutated genes. Subsequent analysis suggested that patients in the BCIPI-High subgroup were more sensitive to anti-PD-L1 immunotherapy than those in the BCIPI-Low subgroup | ||
| 520 | |a Conclusions: The newly established BCIPI is a valuable tool for predicting overall survival outcomes and immunotherapeutic responses in patients with bladder cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AJCC, American Joint Committee on Cancer | |
| 650 | 4 | |a Anti-PD-L1, Antitumor response to atezolizumab | |
| 650 | 4 | |a BCG, Bacillus Calmette-Guerin | |
| 650 | 4 | |a BCIPI, Bladder cancer immune prognostic index | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a CNVs, Copy number variations | |
| 650 | 4 | |a FDA, Food and Drug Administration | |
| 650 | 4 | |a FPKM, Fragments per kilobase per million | |
| 650 | 4 | |a Genomic | |
| 650 | 4 | |a ICI, Immune checkpoint inhibitor | |
| 650 | 4 | |a IHC, Immunohistochemistry | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a MES, Mesenchymal transition | |
| 650 | 4 | |a NES, Normalized enrichment score | |
| 650 | 4 | |a Overall survival | |
| 650 | 4 | |a RMA, Robust multiarray average | |
| 650 | 4 | |a RMS, Restricted mean survival | |
| 650 | 4 | |a TPM, Transcripts per kilobase million | |
| 650 | 4 | |a ssGSEA, Single-sample GSEA | |
| 700 | 1 | |a Chen, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Qintao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Jialin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Chaozhao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Computational and structural biotechnology journal |d 2012 |g 21(2023) vom: 01., Seite 74-85 |w (DE-627)NLM218960549 |x 2001-0370 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g day:01 |g pages:74-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.csbj.2022.11.052 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |b 01 |h 74-85 | ||